Europe smoking cessation and nicotine de-addiction market is projected to register 25.1% CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Europe Smoking Cessation and Nicotine De-Addiction Market- By Product Type (With Nicotine and Without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation), By Country (U.K., Germany, France, Russia, Italy, Switzerland, Spain, Belgium, Netherlands, Turkey and Rest of Europe)-Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Europe smoking cessation and nicotine de-addiction market:
- Increasing disposable income boosts the demand of with nicotine products like e-cigarettes in the region.
- Prevalence of e-cigarettes is increasing and also the population is also looking for other alternatives
Market Players:
The key players of Europe smoking cessation and nicotine de-addiction market are:
- Imperial brands
- Pfizer Inc.
- Dr. Reddy’s Laboratories Ltd
- Glaxosmithkline Plc.
- Alkalon a/s
- British American Tobacco
- Cambrex Corporation
- Cipla Inc.
- Fertin Pharma
- Johnson & Johnson Services, Inc.
- Perrigo Company Plc